Abstract: Oilfield treatment compositions contain water, hydrochloric acid at a concentration between 15 wt % and 45.7 wt % and a first and second fixing agent. The first fixing agent comprises urea, a urea derivative or both. The second fixing agent may be a mixture or amines and alcohols. These compositions provide corrosion inhibition when exposed to steel. The compositions may also contain an inhibitor aid.

Abstract: Oilfield treatment compositions contain water, hydrochloric acid at a concentration between 15 wt % and 45.7 wt % and a first fixing agent. The first fixing agent comprises urea, a urea derivative or both. The molar ratio between the first fixing agent and water may be higher than or equal to 0.5, and urea is the dominant solvent species in the compositions. In these compositions the first fixing agent provides corrosion inhibition when exposed to steel. The compositions may also contain a second fixing agent and an inhibitor aid.

Abstract: This invention relates to compositions and methods of removing an organic deposit including introducing a fluid, wherein the fluid comprises at least two non-polar organic solvents and at least two polar organic solvents; allowing the fluid to dissolve at least a portion of the organic deposit; and removing at least a portion of the fluid. This invention relates to compositions and methods of removing an organic deposit including introducing a fluid, wherein the fluid comprises at least two non-polar organic solvents and at least two polar organic solvents, wherein the non-polar organic solvents comprise aromatic naphtha, terpenes, kerosene, and combination thereof, and wherein the polar solvents comprise heavy aromatic naphtha, cyclohexanone, N-2-methyl pyrrolidone, N-ethyl-2-pyrrolidone, and combination thereof, allowing the fluid to dissolve at least a portion of the organic deposit, and removing at least a portion of the fluid.

Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula I: or stereoisomers or pharmaceutically acceptable salts thereof, wherein G, Q, X, Y, R3, R3a, and R3b are defined herein.

Abstract: A wheel for a toy vehicle including a rim comprising at least one spoke radiating from a hub comprising a channel, and an insert configured to be disposed in the channel, wherein the insert is held within the channel such that the insert appears to be integral with the at least one spoke.

Abstract: The current application discloses fluids and methods for treating a subterranean formation penetrated by a wellbore, such as hydraulic fracturing. In one aspect, there is provided an oilfield fluid comprising chitosan at an amount sufficient to inhibit the growth of bacterial in the oilfield fluid. In another aspect, there is provided a method of preserving an oilfield fluid containing adding chitosan at a concentration that is sufficient to inhibit the growth of bacteria in the oilfield fluid. In a further aspect, there is provided a method of treating a subterranean formation penetrated by a wellbore, comprising preparing a treatment fluid, adding chitosan at a concentration sufficient to inhibit the growth of bacteria in the treatment fluid, introducing the mixture to the subterranean formation, and treating the subterranean formation with the mixture.

Abstract: The current application discloses fluids and methods for treating a subterranean formation penetrated by a wellbore. In one aspect, there is provided a fluid comprising chitosan and titanate, where the fluid has an increased viscosity compared with a solution containing chitosan without titanate. In another aspect, there is provided a method of using such fluid to treat a subterranean formation penetrated by a wellbore. The method may comprise mixing chitosan and titanate in a carrying medium, forming a gel comprising chitosan and titanate, introducing the gel into a subterranean formation, and treating the subterranean formation with the gel.

Abstract: Disclosed are methods of operating a toy. One disclosed method includes receiving a trigger signal for an event from another toy; determining whether a previous trigger signal has been received; and providing a feedback to the trigger event based on the determination of receipt of the previous trigger signal. Apparatuses are also disclosed for performing the method.

Abstract: In accordance with various embodiments, a set of features are described for enabling an application server platform for telecom based applications. A system for providing an application server for telecom-based applications can include an application server that includes a session initiation protocol (SIP) adapter. The SIP adapter can use a connection oriented protocol and provides interactions with application code in an actor of said application server by means of asynchronized SIP protocol events. The SIP adapter can also provide stateless node mapping to a stateful server node hosting a specific session for the actor.

Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula I: or stereoisomers or pharmaceutically acceptable salts thereof, wherein G, Q, X, Y, R3, R3a, and R3b are defined herein.

Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula I: or stereoisomers or pharmaceutically acceptable salts thereof, wherein G, Q, X, Y, R3, R3a, and R3b are defined herein.

Abstract: In an embodiment, a light refraction illumination device is disclosed. The light refraction illumination device may comprise or include a support member, and a plurality of lenses associated with the support member, wherein each lens from among the plurality of lenses may comprise or include a plurality of concave surfaces. The light refraction illumination device may further comprise or include at least one light source associated with the support member, wherein the at least one light source is configured to emit light, and wherein the at least one light source is positioned relative to the plurality of lenses such that the light is configured to travel through the plurality of concave surfaces.

Abstract: The invention discloses treatment and reuse of oilfield produced water. A method of inhibiting enzymes/bacteria in an aqueous medium for viscosification comprises contacting the aqueous medium with a denaturant and/or a bactericide and thereafter mixing a gelling agent in the aqueous medium. The viscosified fluid can be used as a well treating fluid for fracturing and other applications. A well treatment fluid comprises a metal denaturant and/or a bactericide and a gelling agent in an amount effective to viscosify the fluid. Also disclosed is oilfield produced water denatured with from 1 to 2000 ppm by weight of a zirconium compound.

Abstract: This invention relates to compositions and methods of removing an organic deposit including introducing a fluid, wherein the fluid comprises at least two non-polar organic solvents and at least two polar organic solvents; allowing the fluid to dissolve at least a portion of the organic deposit; and removing at least a portion of the fluid. This invention relates to compositions and methods of removing an organic deposit including introducing a fluid, wherein the fluid comprises at least two non-polar organic solvents and at least two polar organic solvents, wherein the non-polar organic solvents comprise aromatic naphtha, terpenes, kerosene, and combination thereof, and wherein the polar solvents comprise heavy aromatic naphtha, cyclohexanone, N-2-methyl pyrrolidone, N-ethyl-2-pyrrolidone, and combination thereof, allowing the fluid to dissolve at least a portion of the organic deposit, and removing at least a portion of the fluid.

Abstract: Disclosed are methods of operating a toy. One disclosed method includes receiving a trigger signal for an event from another toy; determining whether a previous trigger signal has been received; and providing a feedback to the trigger event based on the determination of receipt of the previous trigger signal. Apparatuses are also disclosed for performing the method.

Abstract: A touch sensitive toy comprising a car body; a sensor having a surface sensitive to the touch of a person, wherein the sensor is attached to the card body such that the surface sensitive to the touch of a person is outwardly facing; a circuit electrically coupled to the sensor, wherein the circuit is programmed to react based on a measurement taken by the sensor.

Abstract: In an embodiment, a light refraction illumination device is disclosed. The light refraction illumination device may comprise or include a support member, and a plurality of lenses associated with the support member, wherein each lens from among the plurality of lenses may comprise or include a plurality of concave surfaces. The light refraction illumination device may further comprise or include at least one light source associated with the support member, wherein the at least one light source is configured to emit light, and wherein the at least one light source is positioned relative to the plurality of lenses such that the light is configured to travel through the plurality of concave surfaces.

Abstract: Novel compounds are provided which are 11 -beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula I: or stereoisomers or pharmaceutically acceptable salts thereof, wherein G, Q, X, Y, R3, R3a, and R3b are defined herein.

Abstract: A treatment fluid for a subterranean formation includes a carrier fluid and an amount of particles including a granular scale inhibitor. The carrier fluid includes a hydratable gel fluid, a crosslinked gel fluid, an acid-based fluid, an oil-based fluid, and/or a visco-elastic surfactant. The particles include a proppant impregnated with the scale inhibitor, a solid particle formed largely from the scale inhibitor, or both. The proppant includes scale inhibitor adsorbed on porous surfaces within the proppant, and/or a porous proppant with scale inhibitor embedded in the bulk porosity of the proppant. The scale inhibitor is present in an amount between about 1% and 5% of a total weight of particles. The particles include scale inhibitor at a sufficient concentration and dissolution rate to provide acceptable scale inhibitor concentrations in produced fluids for production volumes exceeding 500 pore volumes.